mAbs Archives | VxP Biologics

Advanced Development and Manufacturing of Antibody Technologies (ADAMANT)
Gallery
Advanced Development and Manufacturing of Antibody Technologies (ADAMANT)

Advanced Development and Manufacturing of Antibody Technologies (ADAMANT)

To help accelerate MCM development, VxP Biologics has developed its Advanced Development and Manufacturing of Antibody Technologies (ADAMANT) platform. This platform integrates cell libraries, region design and selection techniques, and formulation standards into a high-throughput production format. By optimizing and standardizing antibody design and production, ADAMANT helps biologic developers bring new antibody candidates to the clinical trial stage more rapidly.

By Ray Peck|2018-02-07T09:35:49-05:00October 5th, 2017|Research & Development|0 Comments

Upstream and Downstream Process Optimization is Essential to Cost Containment in Biologics Manufacturing
Gallery
Upstream and Downstream Process Optimization is Essential to Cost Containment in Biologics Manufacturing

Upstream and Downstream Process Optimization is Essential to Cost Containment in Biologics Manufacturing

Improvements throughout the pipeline bring greater biologic yields, as well as higher quality. by Raymond E Peck, CEO of VxP Biologics Improvements throughout the pipeline bring greater biologic yields, as well as lower costs. Bioprocessing is the production of natural or genetically manipulated cells (or other organic parts). In the field of biologic pharmaceuticals, bioprocessing [...]

By Ray Peck|2018-04-05T13:01:46-04:00September 22nd, 2017|Analytical, Manufacturing|0 Comments

Clinical Stage Products
Gallery
Clinical Stage Products

Clinical Stage Products

Emerging technologies offer exciting opportunities for the development of novel therapies. by Susan Thompson, Technical Director at VxP Biologics Although commercial sales are certainly a desirable target for pharmaceutical development, they’re far from the only reason to invest in new products. In a number of fields, pharma developers are partnering with contract manufacturing organizations (CMOs) [...]

By Susan Thompson|2018-02-07T09:33:40-05:00September 3rd, 2017|Research & Development|0 Comments

New Investments and Approvals Spur the Development of Biologics
Gallery
New Investments and Approvals Spur the Development of Biologics

New Investments and Approvals Spur the Development of Biologics

Although still expensive to develop and produce, large molecules are rapidly taking over. by Susan Thompson, Technical Director at VxP Biologics For most of the previous century, much of pharmaceutical research focused on the development of small-molecule “blockbuster” drugs, which treated a wide variety of diseases for a great number of patients, and could thus [...]

By Susan Thompson|2018-02-07T09:33:52-05:00June 18th, 2017|Manufacturing, Research & Development|0 Comments

Development of Biologics – Monoclonal Antibodies
Gallery
Development of Biologics – Monoclonal Antibodies

Development of Biologics – Monoclonal Antibodies

Monoclonal antibody approval success rates vary widely, but are on the increase overall. by Raymond E Peck, CEO of VxP Biologics The human monoclonal antibody (mAb) sector has witnessed tremendous growth since its inception in the early 1980s. Despite a rocky start, new technologies in molecule generation spurred rapid development throughout the 1990s; and in [...]

By Ray Peck|2018-02-07T09:36:56-05:00June 16th, 2017|Research & Development|0 Comments